Salute e Benessere

Treg Cell-based Therapies Clinical Trial Pipeline Appears Robust With 51+ Key…

Key Takeaways from the Treg Cell-based Therapies Pipeline Report Key Takeaways from the Treg Cell-based Therapies Pipeline Report Request a sample and discover the recent advances in Treg cell-based therapies @ Treg Cell-based Therapies Pipeline Outlook The Treg cell-based therapies pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Treg cell-based therapies, inactive and dormant assets, a comprehensive assessment...
PR Newswire
28/10/2024

Emboline, Inc. Files Patent Infringement Suit Against AorticLab s.r.l. Regarding…

The Emboliner is the first device designed to provide complete brain and body protection from ischemic events such as stroke caused by embolic debris released into the bloodstream during transcatheter heart procedures. While transcatheter valve technology and techniques have continued to be refined over the past two decades since the introduction of TAVR, suffering a major debilitating stroke remains a real and persistent threat, and is often cited by patients as being feared more than death…
PR Newswire
28/10/2024

Excipients in Pharmaceuticals: Navigating the Global Market Landscape Through…

This report offers a detailed analysis of the market for pharmaceutical excipients, focusing on the competitive landscape and the revenues and product portfolio of leading companies. It examines trends, challenges, and opportunities, along with market projections through 2029. The report segments the market by excipient types—organic, inorganic, and USP water—as well as specific categories such as carbohydrates (cellulose, sugars, starch), and calcium salts. It also evaluates the three dosage…
PR Newswire
28/10/2024

AB Science receives notice of allowance for European patent covering masitinib…

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS MASITINIB'S INTELLECTUAL PROPERTY ADDING ONE MORE INDICATION WITH LONG TERM PROTECTIONMASITINIB IS IN PHASE 2 IN SICKLE CELL DISEASEParis, October 28, 2024, 5.45pm CETAB Science SA(Euronext - FR0010557264 - AB) today announced that the European Patent Office has issued a Notice of Allowance for a...
Nasdaq GlobeNewswire
28/10/2024

ONWARD® Medical Publishes Closing of Bookbuild Offering

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)EINDHOVEN, the Netherlands, Oct.28, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), announces today the closing of its previously...
Nasdaq GlobeNewswire
28/10/2024

Gastrointestinal Drugs Market Size to Reach $106.30 Billion By 2031 | CAGR 7.5%…

Browse Detailed Analysis: https://www.theinsightpartners.com/reports/gastrointestinal-drugs-market Browse Detailed Analysis:https://www.theinsightpartners.com/reports/gastrointestinal-drugs-market Overview of Report Findings Market Growth : 1. Market Growth : The gastrointestinal drugs market is expected to reachUS$ 59.71 billionby 2023 fromUS$ 106.30 billionin 2031; it is anticipated to register a CAGR of 7.5% during the forecast period. Gastrointestinal drugs are...
PR Newswire
28/10/2024

Dental Implants Market Size to Reach $11.28 Billion By 2031 | CAGR 8.3%: The…

Browse Detailed Analysis: https://www.theinsightpartners.com/reports/dental-implants-market Browse Detailed Analysis: https://www.theinsightpartners.com/reports/dental-implants-market Overview of Report Findings Get Sample Pages in your inbox: https://www.theinsightpartners.com/sample/TIPHE100000866/ Market Segmentation Get Sample PDF Copy:https://www.theinsightpartners.com/sample/TIPHE100000866/ Competitive Strategy and Development Headlines on Dental...
PR Newswire
28/10/2024

Clinical Trials Market Size to Reach $73.33 Billion By 2031 | CAGR 6.8%: The…

Browse Detailed Analysis: https://www.theinsightpartners.com/reports/clinical-trials-market Browse Detailed Analysis:https://www.theinsightpartners.com/reports/clinical-trials-market Overview of Report Findings Market Growth : Get Sample Pages in your inbox:https://www.theinsightpartners.com/sample/TIPRE00006203/ Market Segmentation Get Sample PDF Copy: https://www.theinsightpartners.com/sample/TIPRE00006203/ Competitive Strategy and Development ...
PR Newswire
28/10/2024

Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029…

Browse in-depth TOC on "Artificial Intelligence in Biotechnology Market" Browse in-depth TOC on "Artificial Intelligence in Biotechnology Market" 200 - Tables50 - Figures300 - Pages Based on deployment mode, the AI in biotechnology market is categorized into cloud-based and on-premises. The cloud-based segment accounted for the largest share of AI in biotechnology market in 2023. Each deployment type offers distinct advantages and is chosen based on factors like data...
PR Newswire
28/10/2024

HOPO Therapeutics Awarded Up to $226 Million from BARDA for Advanced Development…

There are no approved oral therapies to treat individuals exposed to radioactive heavy metals like plutonium, americium, and curium. In the event of a radiological or nuclear disaster, treatment with a decorporation agent – a drug designed to bind and accelerate the clearance of heavy metals from the body – is the only practical means to mitigate the risk of radiation poisoning. HOPO Therapeutics is developing decorporation agents that can be taken orally, with the aim of providing rapid...
Nasdaq GlobeNewswire
28/10/2024

TeleVox Applauded by Frost & Sullivan for Improving Patient Experience through…

TeleVox has a comprehensive portfolio of best-in-breed solutions that cover the holistic patient journey, including preventative care, discovery care, specialty diagnosis and treatment, appointment booking and preparation, and chronic disease management. This comprehensive portfolio is a key differentiator for TeleVox, as it bridges the gap across various touchpoints in the patient journey, irrespective of where the patient is in the process. It ensures easier provider access to functionalities…
PR Newswire
28/10/2024

Michael McDonnell, Executive Vice President and Chief Financial Officer to…

Robin Kramer, Chief Accounting Officer, to Succeed Him BiogenInc. (Nasdaq: BIIB) today announced that Michael McDonnell, Biogen's Executive Vice President and Chief Financial Officer, plans to retire from the company on February 28, 2025. Upon Mr. McDonnell's retirement, Robin Kramer, currently Chief Accounting Officer at Biogen, will assume the role of Chief Financial Officer (CFO). In the coming weeks and months, Mr. McDonnell will work closely with Ms. Kramer to ensure a smooth...
Nasdaq GlobeNewswire
28/10/2024

Lupin to focus on the development of inhalers with near-zero global warming…

Richard Dekhuijzen, em, professor of pulmonology at the Radboud university medical center in Nijmegen, the Netherland said, "The development of inhalers with near-zero global warming potential serves two major objectives: firstly, a maximal reduction of their environmental impact, and secondly, as important, keeping these medications available for those patients who really need these type of inhalers since they are unable to use dry powder inhalers." Richard Dekhuijzen, em, professor…
PR Newswire
28/10/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 28 October 2024– On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under the...
Nasdaq GlobeNewswire
28/10/2024

Evaxion to announce business update and third quarter 2024 financial results on…

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 13:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and...
Nasdaq GlobeNewswire
28/10/2024

Buyback of Class B shares in Essity during week 43, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
28/10/2024

Sai Life Sciences receives EIRs from USFDA for India R&D & Manufacturing…

HYDERABAD, India, Oct.28, 2024(GLOBE NEWSWIRE) -- Sai Life Sciences, the fastest-growing IndianContract Research, Development and Manufacturing Organization (CRDMO) [1],announced that it has received Establishment Inspection Reports (EIR) from the US Food and Drug Administration (USFDA) for its R&D (Unit II, Hyderabad), and Manufacturing (Unit IV, Bidar) sites in India.The General Good Manufacturing Practices (GMP) audit was conducted at the integrated R&D campus...
Nasdaq GlobeNewswire
28/10/2024

Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team…

David Epstein, Chair & Chief Executive Officer of Ottimo Pharma, said: "This new medicine is exquisitely designed and offers large potential benefits to patients across a wide range of solid tumors. It will be exciting to scale the team and deliver on the promise to patients." David Epstein, Chair & Chief Executive Officer of Ottimo Pharma, said:"This new medicine is exquisitely designed and offers large potential benefits to patients across a wide range of solid tumors…
PR Newswire
28/10/2024

NaoTrac to Redefine Surgical Navigation Robotics at MEDICA 2024

With hundreds of successful cases, NaoTrac has already been instrumental in helping surgeons save lives and enhance surgical outcomes, exemplifying Brain Navi's commitment to delivering cutting-edge medical technology solutions. With hundreds of successful cases, NaoTrac has already been instrumental in helping surgeons save lives and enhance surgical outcomes, exemplifyingBrain Navi'scommitment to delivering cutting-edge medical technology solutions. In addition to NaoTrac,Brain Navi...
PR Newswire
28/10/2024

AdJane Announces its Official Launch as a Leader in Vaccine Adjuvants

For more information about AdJane and our commitment to advancing public health please visit www.AdJane.com For more information about AdJane and our commitment to advancing public health please visitwww.AdJane.com About the company AdJane specializes in the development of vaccine adjuvants aimed at enhancing vaccine efficacy. At the heart of AdJane's innovations lies our proprietary Ada-24 adjuvant. This adjuvant has been developed through a strategic collaboration and long-term...
PR Newswire
28/10/2024

Explore Wincomm's Latest Innovations in Medical AI PCs at Medica 2024

At Medica 2024, Wincomm will unveil its next-generation medical AI PCs, featuring the latest Intel® 13th and 14th generation Core processors (Raptor Lake). These systems are engineered to deliver high-performance computing for precision medicine, offering support for Nvidia® and Intel® GPU cards. This combination provides healthcare professionals with superior computational and graphical capabilities, essential for advanced medical imaging and diagnostics. AtMedica 2024, Wincomm will unveil...
PR Newswire
28/10/2024

ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its…

ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicinesMulti-year collaboration will use ViaNautis' non-immunogenic polyNaut® nanovesicles that precisely target specific tissues and cell typesCambridge, UK, 28 October, 2024– ViaNautis Bio ("ViaNautis" or the "Company"), a groundbreaking biotechnology company at the forefront of delivering targeted genetic nanomedicines, today…
Nasdaq GlobeNewswire
28/10/2024

Philips delivers strong margin improvement; flat comparable sales due to further…

Third-quarter highlightsGroup sales amounted to EUR 4.4 billion, with flat comparable sales growthIncome from operations was EUR 337 millionAdjusted EBITA margin increased by 160 basis points from 10.2% to 11.8% of salesOperating cashflow of EUR 192 million, with a free cashflow of EUR 22 millionComparable order intake decreased by 2%, due to decline in ChinaOutlook for full-year 2024 revised to reflect deteriorated demand in China: comparable sales growth within an updated...
Nasdaq GlobeNewswire
28/10/2024

BioSenic provides third quarter 2024 Business Update

BioSenic provides third quarter 2024 Business UpdateBioSenic is actively seeking one or more new assets through a merger or acquisition process Mont-Saint-Guibert, Belgium, October 28, 2024, 7.00 am CEST – Regulated Information - BIOSENIC(Euronext Brussels and Paris: BIOS), theclinical stage company specializing in serious autoimmune and inflammatory diseases, as well as cell repair, today provides its business update for the third quarter, ended 30 September 2024...
Nasdaq GlobeNewswire
28/10/2024
Altri  Comunicati